Beigene, Ltd. ((ONC)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: BeiGene, Ltd. is conducting a Phase 2 study titled A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib. The study aims to assess the safety of zanubrutinib in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma who are intolerant to previous treatments with ibrutinib or acalabrutinib.
Intervention/Treatment: The intervention being tested is zanubrutinib, an oral drug administered at 160 mg twice daily or 320 mg once daily. It targets B-cell lymphomas and is intended to offer a safer alternative for patients intolerant to other Bruton tyrosine kinase inhibitors.
Study Design: This interventional study follows a single-group model without masking, focusing on treatment as its primary purpose. Participants are allocated to receive zanubrutinib, and the study does not involve a control group.
Study Timeline: The study began on October 15, 2019, and is currently active but not recruiting. The last update was submitted on June 23, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
Market Implications: This study update could positively influence BeiGene’s stock performance by demonstrating the potential of zanubrutinib as a safer treatment option, potentially increasing investor confidence. The study’s progress is also relevant in the context of competition within the B-cell lymphoma treatment market.
Closing Sentence: The study is ongoing, with further details available on the ClinicalTrials portal.